

Serial No.: 09/576,094
Attorney Docket No. 2C03.1-191
CIBA Docket No.: SU/V-31536AJC1

CLAIM AMENDMENTS

Please amend the claims (~~strikethrough~~ and [] indicating deletion and underline indicating insertion), and add new claims as follows:

1. (previously amended) A positive power anterior chamber ocular implant for placement in the anterior chamber of a phakic eye comprising a positive artificial refracting lens having at least one convex surface and a means for positioning the lens in the anterior chamber of the eye, wherein contact between the positive refracting lens and other anatomic bodies is avoided, wherein the means for positioning avoids contact with the iris and corneal endothelium;

wherein said means for positioning the positive refracting lens comprises two haptics providing a four-point attachment, each haptic having an "S" configuration with a smooth transition portion extending normal to a peripheral edge of the lens, an intermediate beam extending from the transition portion and having a length of approximately 5.25 mm, and a concavely curved outer portion extending from the intermediate beam, wherein each haptic has a thickness in the range of 0.25 mm to 0.35 mm at the point of attachment to said lens.

- 2-5 (cancelled)
6. (original) The implant according the claim 1, wherein the implant is coated with a compatible sulfated polysaccharide medicament.

Serial No.: 09/576,094
Attorney Docket No. 2C03.1-191
CIBA Docket No.: SUV-31536A/C1

7. (original) The implant according to claim 6, wherein the sulfated polysaccharide is selected from the group consisting of heparin, heparin sulfate, chondroitin sulfate, dermatan sulfate, chitosan sulfate, xylan sulfate, dextran sulfate, and sulfated hyaluronic acid.
8. (original) The implant according to claim 1, wherein the artificial refracting lens is fabricated from compounds selected from the group consisting of polymethylmethacrylate, methacrylate, poly-2-hydroxyethyl methacrylate, methylmethacrylate copolymers, siloxanylalkyl, fluoroalkyl and aryl methacrylates, silicone, silicone elastomers, polysulfones, polyvinyl alcohols, polyethylene oxides, copolymers of fluoroacrylates and methacrylates, polymers and copolymers of hydroxyalkyl methacrylates, methacrylic acid, acrylic acid, acrylamide, methacrylamide, N, N-dimethylacrylamide, and N-vinylpyrrolidone.
9. (original) The implant according to claim 1, wherein the refracting lens is foldable.
10. (original) The implant according to claim 1, wherein the refracting lens is rigid.
- 11-20 (cancelled)

Serial No.: 09/576,094
Attorney Docket No. 2C03.1-191
CIBA Docket No.: SU/V-31536A/C1

21. (currently amended) An ocular implant comprising:
an optic lens having an anterior surface, a posterior surface, and a peripheral edge between the anterior surface and the posterior surface;
two haptics affixed to said lens, each said haptic having a generally "S"-shaped configuration with a smooth transition portion extending normal to the peripheral edge of the lens, an intermediate beam, having a length of about 5.25 mm, extending from the transition portion, and a concavely curved outer portion extending from the intermediate beam to define a first attachment point at the juncture of the intermediate beam and the outer portion, and a second attachment point at a distal end of the outer portion.

22. (currently amended) The ocular implant of Claim 21, wherein at least one of the anterior surface and the posterior surface is [[are]] convex.

23. (previously presented) The ocular implant of Claim 21, wherein both of the anterior surface and the posterior surface are convex.

24. (previously presented) The ocular implant of Claim 21, wherein said lens has a positive optical power.

25. (previously presented) The ocular implant of Claim 21, wherein said lens is foldable.

26. (previously presented) The ocular implant of Claim 21, wherein the transition portion of each haptic has a thickness of between 0.25 mm to 0.35 mm.

27. (cancelled)

28. (previously presented) The ocular implant of Claim 21, having a vault of between 0.8 mm and 1.2 mm.

Serial No.: 09/576,094
Attorney Docket No. 2C03.1-191
CIBA Docket No.: SUV-31536A/C1

29. (previously presented) The ocular implant of Claim 21, having a saggita value of between 1.2 mm and 1.75 mm.
30. (previously presented) The ocular implant of Claim 21, wherein said transition portion comprises a smooth concave curvature.
31. (previously presented) The ocular implant of Claim 30, wherein the smooth concave curvature of said transition portion has a radius of curvature of less than 0.4 mm.
32. (previously presented) The ocular implant of Claim 21, having an overall omega value of 12 mm to 14 mm.
33. (currently amended) A positive power anterior chamber ocular implant for placement in the anterior chamber of a phakic eye, said ocular implant comprising a lens having an anterior surface, a posterior surface, and a peripheral edge between the anterior surface and the posterior surface, at least one of the anterior surface and the posterior surface being convex, said ocular implant further comprising a pair of haptics attached to said lens, said pair of haptics providing a four-point attachment wherein each haptic has a generally "S"-shaped configuration with a smooth transition portion extending normal to the peripheral edge of the lens, an intermediate beam, having a length of about 5.25 mm, extending from the transition portion, and a concavely curved outer portion extending from the intermediate beam to define a first attachment point at the juncture of the intermediate beam and the outer portion, and a second attachment point at a distal end of the outer portion.
34. (previously presented) The ocular implant of Claim 33, wherein the transition portion of each haptic has a reduced thickness of between 0.25 mm to 0.35 mm.
35. (cancelled)

Serial No.: 09/576,094
Attorney Docket No. 2C03.1-191
CIBA Docket No.: SUV-31536A/C1

36. (previously presented) The ocular implant of Claim 33, having a vault of between 0.8 mm and 1.2 mm.
37. (previously presented) The ocular implant of Claim 33, having a saggita value of between 1.2 mm and 1.75 mm.
38. (previously presented) The ocular implant of Claim 33, wherein said transition portion comprises a smooth concave curvature.
39. (previously presented) The ocular implant of Claim 38, wherein the smooth concave curvature of said transition portion has a radius of curvature of less than 0.4 mm.
40. (previously presented) The ocular implant of Claim 33, having an overall omega value of 12 mm to 14 mm.
41. (new) The implant of Claim 21, wherein the implant is coated with a compatible sulfated polysaccharide medicament.
42. (new) The implant of Claim 41, wherein the sulfated polysaccharide is selected from the group consisting of heparin, heparin sulfate, chondroitin sulfate, dermatan sulfate, chitosan sulfate, xylan sulfate, dextran sulfate, and sulfated hyaluronic acid.
43. (new) The implant of Claim 21, wherein the artificial refracting lens is fabricated from compounds selected from the group consisting of polymethylmethacrylate, methacrylate, poly-2-hydroxyethyl methacrylate, methylmethacrylate copolymers, siloxanylalkyl, fluoroalkyl and aryl methacrylates, silicone, silicone elastomers, polysulfones, polyvinyl alcohols, polyethylene oxides, copolymers of fluoroacrylates and methacrylates, polymers and copolymers of hydroxyalkyl methacrylates, methacrylic acid, acrylic acid, acrylamide, methacrylamide, N, N-dimethylacrylamide, and N-vinylpyrrolidone.

Serial No.: 09/576,094
Attorney Docket No. 2C03.1-191
CIBA Docket No.: SU/V-31536A/C1

44. (new) The implant of Claim 33, wherein the implant is coated with a compatible sulfated polysaccharide medicament.
45. (new) The implant of Claim 44, wherein the sulfated polysaccharide is selected from the group consisting of heparin, heparin sulfate, chondroitin sulfate, dermatan sulfate, chitosan sulfate, xylan sulfate, dextran sulfate, and sulfated hyaluronic acid.
46. (new) The implant of Claim 33, wherein the artificial refracting lens is fabricated from compounds selected from the group consisting of polymethylmethacrylate, methacrylate, poly-2-hydroxyethyl methacrylate, methylmethacrylate copolymers, siloxanylalkyl, fluoroalkyl and aryl methacrylates, silicone, silicone elastomers, polysulfones, polyvinyl alcohols, polyethylene oxides, copolymers of fluoroacrylates and methacrylates, polymers and copolymers of hydroxyalkyl methacrylates, methacrylic acid, acrylic acid, acrylamide, methacrylamide, N, N-dimethylacrylamide, and N-vinylpyrrolidone.